Long COVID: New Research on Immune, Neurological, and Pediatric Impacts

A recent study has found that long COVID in children is linked to worse academic performance, attention difficulties, and social challenges, highlighting the growing concern about the pandemic’s lasting effects on young people’s development and daily functioning.

The research, published by CIDRAP, analyzed data from children who had experienced long COVID and found measurable impacts on their school grades, ability to focus in class, and interactions with peers. These effects were observed even after accounting for other variables, suggesting a direct association between prolonged symptoms of SARS-CoV-2 infection and declines in cognitive and social domains critical to childhood development.

These findings align with broader scientific efforts to understand how SARS-CoV-2 affects the developing brain and body over time. A separate study published in Nature emphasized the need for further research into the neurological and neurodevelopmental consequences of SARS-CoV-2 and multisystem inflammatory syndrome in children (MIS-C), particularly as they relate to long-term outcomes in pediatric populations. Researchers noted that while acute infections may present differently in children compared to adults, the potential for lasting neurological effects remains understudied and warrants increased attention in follow-up research.

Additional support comes from the RECOVER Initiative, a large-scale national effort to study long COVID across age groups. In its March 2026 update, RECOVER reported on findings from its pregnancy study, which found no significant differences in neurodevelopmental outcomes at 12 to 18 months of age among infants whose mothers had COVID-19 during pregnancy—specifically those exposed to the Omicron variant—compared to those whose mothers did not. This suggests that while in utero exposure to SARS-CoV-2 may not adversely affect early brain development in some cases, postnatal infection and the development of long COVID in children themselves may carry different risks.

Further reinforcing the significance of these findings, a separate analysis published in Nature Medicine examined biomarkers associated with long COVID and found no evidence of ongoing neuronal injury or neuroinflammation in patients months after infection. Measures of neurofilament light (NfL) and glial fibrillary acidic protein (GFAP)—markers linked to nerve cell damage and astrocyte activation—were not significantly different between long COVID patients and recovered controls. While some inflammatory markers showed nominal elevations, they did not hold up after statistical correction for multiple comparisons, suggesting that persistent symptoms may not be driven by active central nervous system inflammation or neurodegeneration in all cases.

Taken together, these studies point to a complex picture of long COVID in children: one where functional impacts on learning, attention, and social life are observable and measurable, even when traditional biomarkers of brain injury or inflammation are absent. This disconnect between clinical symptoms and detectable biological markers underscores the need for more sensitive diagnostic tools and longitudinal research that tracks children over time to understand the full scope of long COVID’s effects.

Experts involved in these studies continue to stress the importance of including pediatric populations in long COVID research, noting that children may experience the condition differently than adults and that their developmental trajectories make early identification and support crucial. As research progresses, the focus remains on distinguishing between direct viral effects, immune-mediated responses, and other contributing factors to better inform clinical care and public health guidance for affected children and their families.